50 results
425
ADAP
Adaptimmune Therapeutics Plc
22 May 23
Business combination disclosure
7:01am
by TCR2 are available free of charge on TCR2’s website at https://investors.tcr2.com/ or by contacting TCR2’s Investor Relations Department at https … at https://www.adaptimmune.com/investors-and-media/sec-filings or by contacting Adaptimmune’s Investor Relations Department at ir@adaptimmune.com
8-K
ADAP
Adaptimmune Therapeutics Plc
22 May 23
Other Events
6:59am
by TCR2 are available free of charge on TCR2’s website at https://investors.tcr2.com/ or by contacting TCR2’s Investor Relations Department at https … ://www.adaptimmune.com/investors-and-media/sec-filings or by contacting Adaptimmune’s Investor Relations Department at ir@adaptimmune.com.
Participants
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
://investors.tcr2.com/ or by contacting the Company’s Investor Relations Department at https://investors.tcr2.com/contact-ir. Copies of the documents filed … Parent’s Investor Relations Department at IR@adaptimmune.com.
Participants in the Solicitation
Parent, the Company and certain of their respective
8-K
EX-10.1
dzsbdzyoiinbpsupa4
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-99.1
2fw4pm97in162 ddund
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
NT 10-K
ikz27968stddc5xov
1 Mar 22
Notice of late annual filing
4:30pm
8-K
EX-99.1
je0hbgwmmclo m3x
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
csae1qrtm1zocmg99s
13 Sep 21
Other Events
7:08am
8-K
zxc6nl rz
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
hxwuf
20 Nov 20
Regulation FD Disclosure
7:36am
S-3ASR
EX-1.2
8b532gfp9b
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-1.1
zas2x slx44
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.2
1a80bqk6pkuagdzwd0z
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
c6e1zl7k4qsylkixlz0
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm